Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRACE multispecific T-cell therapy for refractory CMV, EBV, or adenovirus infection after allogeneic HSCT
NL-OMON59572Phase 3Recruiting
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Oct 2019
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial in cytomegalovirus disease (CMV), Epstein-Barr virus infection and adenoviral infection, sponsored by Universitätsklinikum Freiburg. Primary endpoints: Viral clearance and Progression. Started Oct 2019; status: recruiting.
02
Conditions
cytomegalovirus disease (CMV)Epstein-Barr virus infectionadenoviral infection
Beyond the preview
Go deeper on NL-OMON59572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59572.